Nath Bio-Genes Q2 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
No
Order
No
Capex
No
0 of 5 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- Cotton sales expected to grow 15%-20% annually.
- Paddy sales projected to increase 10%-15%.
- Vegetable segment anticipated to grow 20%-25%.
- Plant nutrient supplements forecasted to expand rapidly with 25%-30% growth, contributing about 10% of current revenue and targeted to grow to 30%.
- Diversified product portfolio including maize, bajra, mustard, cotton, paddy, vegetables, and supplements supports balanced growth.
- Overall company growth targeted conservatively at 15%+, with potential upside if crop segments perform well.
- Uzbekistan JV expected to scale seed production post initial trial success, potentially doubling production by next year.
- Philippines export market viewed as supplementary "cherry on the cake," with uncertain but potential upside.
- Revenue goal of crossing 500 crores targeted within 2-3 years, indicating steady top-line expansion driven by current and new products.
See what Nath Bio-Genes management said on margin guidance — free account, 30 seconds.
Fundraise plans
No- No current plans for CAPEX expenditure on plant and machinery, implying no immediate major funding needs (Page 20).
- The company has maintained nearly zero long-term debt for about 5-7 years and pays interest only on working capital (Pages 15, 17).
- Working capital is well managed and funded through advance bookings and bankers without raising new bank debt for nearly three years (Page 17).
- No term loans exist currently; any short-term funds are raised via short-duration NCDs and customer deposits (Page 15).
- No mention of any ongoing or planned equity fundraising during the call.
- The focus appears on organic growth and operational stability with no talk of inorganic growth or fundraising until crossing a revenue threshold of 500 crores (Page 9).
- Overall, no plans for new fundraising through debt or equity were indicated in the discussion.
See what Nath Bio-Genes management said on order book — free account, 30 seconds.
Capex plans
No- No CAPEX (capital expenditure) on plant and machinery is planned for this year or next year.
- The company relies on vendors for processing rather than investing in own plant and machinery, leading to low CAPEX, saving on depreciation, maintenance, and breakage costs.
- Over the past 5-7 years, there has been hardly any CAPEX recorded in the balance sheets.
- Strategic growth plans focus on organic growth with continued emphasis on diversifying portfolios (cotton, paddy, vegetables, plant nutrient supplements).
- The company is exploring opportunities in Uzbekistan with ongoing investment (about US$7-8 lakh so far) and hopes to scale based on performance by early next year.
- Expansion in exports, such as in the Philippines, is considered a potential growth avenue but not a core dependency.
- No inorganic growth via JV currently; consideration may come after crossing ₹500 crore revenue mark.
Track Nath Bio-Genes — get its next earnings analysis in your feed
Margin guidance
Category 3- The company targets a consistent sales growth of around 15% plus annually, with optimism for even 20-25% in some segments like vegetables and supplements.
- Cotton expected to grow 15-20%, paddy 10-15%, vegetables 20-25%, supplements 25-30%, contributing to overall growth.
- Gross profit margin maintained around 51-53%, with focus on product mix to sustain margins despite volume fluctuations.
- PAT growth expected in the range of 15-20%, supported by both existing and new product portfolios, including potential growth from Uzbekistan and Philippines markets.
- Management is conservative, expecting 15%+ growth but open to higher if achieved.
- EBITDA for H1 FY25 was ₹42.18 crores, profit after tax was ₹36.78 crores, reflecting steady profitability.
- No significant CAPEX planned; focus on optimizing working capital and leveraging vendor processing keeps costs controlled, supporting margins and profits.
- Expansion and diversification across crops and supplements expected to drive steady operating earnings growth.
Order book
No- Nath Bio-Genes does not maintain a traditional advance order book like manufacturing industries.
- Instead, the company operates on an advanced booking basis through advance sales.
- Last year, advance bookings amounted to approximately ₹70-80 crores for the next year.
- There is no concept of formal advance orders as seed sales depend on seasonal demand and advance bookings.
- The company emphasizes working capital funded by advance bookings and bank facilities without increasing bank debt for about three years.
- No specific pending or current orderbook figures are mentioned.
How does Nath Bio-Genes rank vs peers in Agricultural Food & other Products?
Pro featureHow does Nath Bio-Genes rank in Agricultural Food & other Products?
Compare Nath Bio-Genes against every Agricultural Food & other Products company (Q2 FY25) on revenue, margins and earnings-call signals.
Continue your research
What Nath Bio-Genes's management said in earlier quarters
Others in Agricultural Food & other Products this season
- Dwarikesh Sugar Industries Ltd (Q4 FY23)
If you can provide a valid transcript or document, I will be happy to assist with your query. Key concall takeaways from Dwarikesh Sugar Industries Ltd's Q4…
- Dwarikesh Sugar Industries Ltd (Q3 FY23)
The provided PDF page contains a "500 . Key concall takeaways from Dwarikesh Sugar Industries Ltd's Q3 FY23 earnings call — and how it ranks against sector…
- Chamanlal Setia (Q1 FY27)
Management is optimistic about sustaining EBITDA margins (12-14%) with profitable business mix. Key concall takeaways from Chamanlal Setia's Q1 FY27 earnings…
- Kaveri Seed Co. (Q1 FY27)
100 crores revenue in vegetables within 3 to 5 years. Key concall takeaways from Kaveri Seed Company Ltd's Q1 FY27 earnings call — and how it ranks against…